WHO
WE ARE

Brainz Bioscience is a bioscience business development consulting company founded 2012 by the bioscience business development consultant Christos Boukouvalas based at Bavarian Business Center, Nuremberg, Germany.

Christos Boukouvalas has over 20 years’ experience in Cell Biotechnology, Biobanking and molecular biotechnology.

It’s focused in technology transfer, business development and commercialization services in the fields of biobanking, regenerative medicine, immune cells banking, tissue engineering, adoptive therapies, medical devices and molecular biotechnology.

The aim of Brainz Bioscience is to offer to the European and the international markets state of the advanced business development services, technology transfer as well as to participate in research programs and clinical trials.

Brainz Bioscience has a worldwide network of partners and collaborators in Europe, Asia, Middle East, South & North America and Australia who support the implementation plans of the its projects.

Brainz Bioscience in collaboration with distinguished Academic Professors and research centers set up research projects focused in new services and applications in the field of Stem Cells, Genomics, Molecular Analysis and Regenerative Medicine.

CORE
VALUES

We offer advanced bioscience business development services following the most recent advances in the field of Biomedical Technology, Regenerative Medicine, molecular biotechnology and Biobanking

We implement patented, reliable protocols and methods under strict guidelines, aiming to contribute to the improvement of patients’ quality of life and the prevention of disease.

We are open to new collaborations and new challenges.

We always strive to improve our capabilities, while remaining human, discreet and worthy of our clients’ and collaborators’ trust.

Mission Statement/

Brainz Bioscience aims to establish one of the biggest networks of cell-based, anti-aging and regenerative medicine applications and treatments.
Brainz Bioscience aims to contribute to the development a paradigm-shift system and network for the collection, processing and cryopreservation of immune cells banking, making it more flexible, more affordable, ensuring better quality and quantity of immune cells both for private and public use.
Develop & license of regenerative & adoptive treatments and applications for cancer, anti-aging, MS, ALS, diabetes, orthopedics and skin regeneration by using autologous or allogenic cells and advance tissue engineering and reprogramming techniques.
Furthermore, to be one of the first companies that will develop commercial custom-made autologous organs of the human body for transplant by using cells and three-dimensional printing techniques.
A percentage of the company’s profits will be invested to financing applications of young and promising scientists who are not able to support them financially.

OUR TEAM/

Prof. Georgios Koliakos

CEO of Biohellenika S.A

Christos Boukouvalas

CEO

Sir. Benjamin Tantiansu

Dr. Gabriel Veridge PhD

CEO Prometheus Biomedical

Oliver Papavlasopoulos

Dr. Eumorphia Remboutsika PhD

OUR PARTNERS/